Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PYGB | P11216 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25518922 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL14051305 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL9914082 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL14025370 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL18102361 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL22311649 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL11946954 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL22311199 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL22311210 | 1.00 | ALDH1A1 (0.63) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL9914084 | 0.89 | ALDH1A1 (0.57) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | ACADEMIA SINICA (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180195070-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | ALDH1A1 3244/4885THRB 1069/4885MAPK1 3600/4885 |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | ALDH1A1 3244/4885THRB 1069/4885MAPK1 3600/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | ALDH1A1 1280/4885THRB 1556/4885MAPK1 4081/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | ALDH1A1 1280/4885THRB 1556/4885MAPK1 4081/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | ALDH1A1 3256/4885THRB 931/4885MAPK1 3714/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | ALDH1A1 3101/4885THRB 833/4885MAPK1 4227/4885 |
| US-10294474-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | ALDH1A1 3101/4885THRB 833/4885MAPK1 4227/4885 |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | GAA, MAN2B1, CLN6 | ALDH1A1 1851/4885THRB 2967/4885MAPK1 4361/4885 |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | ALDH1A1 3158/4885THRB 2083/4885MAPK1 4293/4885 |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | ALDH1A1 3215/4885THRB 628/4885MAPK1 3554/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | ALDH1A1 3244/4885THRB 1069/4885MAPK1 3600/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | ALDH1A1 3244/4885THRB 1069/4885MAPK1 3600/4885 |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | NGLY1, NRDC, MGAT3 | ALDH1A1 3782/4885THRB 128/4885MAPK1 2346/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | ALDH1A1 1280/4885THRB 1556/4885MAPK1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.